Company intelligence / Profile preview

Angionetics, Inc.

San Diego, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Angionetics is advancing Generx (alferminogene tadenovec/Ad5FGF-4), an angiogenic gene therapy product candidate in Phase 3 clinical trials. The therapy is designed to improve cardiac perfusion by promoting the growth of microvasculature in ischemic cardiac tissue. The product received Fast Track designation from the FDA in February 2017, and the Phase 3 "AFFIRM" clinical study is evaluating Generx as a one-time administration for the treatment of refractory angina due to late-stage coronary artery disease[2][3][5].

Therapeutic areas: Cardiovascular
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

alferminogene tadenovec

Phase 3

Indications: Refractory angina, Myocardial ischemia, Coronary artery disease

Partnerships

Huapont Life Sciences (China)

Beyond the preview

Go deeper on Angionetics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angionetics, Inc..

Explore the full profile